Broadly neutralizing antibodies against HIV
AssigneeUniversität zu Köln
InventorsFlorian Klein, Henning Grüll, Philipp Frederik Schommers
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to monoclonal human antibodies or binding fragments thereof which are directed against the CD4 binding site of the human immunodeficiency virus HIV-1, a pharmaceutical composition comprising such monoclonal human antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by the human immunodeficiency virus HIV-1.
Claims7
A method comprising:
- administering a pharmaceutical composition to a human subject infected with HIV-1, wherein the pharmaceutical composition comprises:
- a recombinant human monoclonal anti-human immunodeficiency virus (HIV) antibody comprising a human heavy chain and a human light chain,
- wherein the human heavy chain comprises a human heavy chain variable domain comprising the amino acid sequence according to SEQ ID NO:
- 1 recombinantly joined to a human heavy chain constant domain, and
- wherein the human light chain comprises a human light chain variable domain comprising the amino acid sequence according to SEQ ID NO:
- 2 recombinantly joined to a human light chain constant domain;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.